Regulatory Expansion into Frontline Therapy
On February 18, 2015, Celgene Corporation announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Revlimid (lenalidomide) in combination with dexamethasone to include patients newly diagnosed with multiple myeloma (NDMM). While the combination was previously approved in 2006 for patients who had received at least one prior therapy, this decision marks a significant paradigm shift by allowing the regimen to be used as a first-line treatment option. The expansion provides clinical validation for starting and maintaining patients on Revlimid from the point of initial diagnosis to improve long-term outcomes.
Clinical Validation via the Phase III FIRST Trial
The FDA approval was primarily based on the safety and efficacy results from the FIRST trial (MM-020/IFM 07-01), a large-scale Phase III study involving 1,623 newly diagnosed patients who were not candidates for stem cell transplant. The trial compared continuous Revlimid plus dexamethasone (Rd Continuous) administered until disease progression against a fixed 18-month regimen of melphalan, prednisone, and thalidomide (MPT). A secondary analysis also evaluated a fixed duration of 18 cycles of Rd (Rd18).
Significant Improvements in Progression-Free and Overall Survival
The primary endpoint of the FIRST trial was progression-free survival (PFS). Results demonstrated that patients in the Rd Continuous arm experienced a significantly longer median PFS of 25.5 months, compared to 21.2 months for those in the MPT arm ($HR=0.72$; $p=0.0001$). Furthermore, an interim analysis conducted in March 2014 revealed a substantial benefit in overall survival (OS). The median OS for the Rd Continuous group was 58.9 months, compared to 48.5 months for the MPT group ($HR=0.75$). This data indicates that continuous treatment with the Rd regimen reduced the risk of death by 25% compared to the MPT triplet.
Safety Profile and Adverse Event Management
The safety analysis for newly diagnosed patients showed that the most common adverse reactions (occurring in 20% or more of patients) across the study arms included diarrhea, anemia, neutropenia, fatigue, and back pain. Other frequently reported symptoms were insomnia, asthenia, rash, decreased appetite, and cough. In the Rd Continuous arm specifically, the most prevalent Grade 3 or 4 complications were neutropenia (27.8%), anemia (18.2%), and pneumonia (11.3%). Other severe reactions included thrombocytopenia, fatigue, and deep vein thrombosis (DVT), which occurred in approximately 5.6% of the continuous treatment group.
Implications for the Management of Multiple Myeloma
The inclusion of Revlimid plus dexamethasone in the prescribing information for first-line treatment reinforces the importance of early intervention with effective immunomodulatory therapies. By providing a treatment pathway that extends from diagnosis through potential progression, healthcare providers can now offer a continuous management strategy designed to delay disease advancement and improve the overall survival of patients who are not eligible for transplant. This approval underscores a continued commitment to evolving the standard of care for the multiple myeloma community.
